Loading...
Loading...
JP Morgan maintained Cintas
CTAS with an Overweight rating and raised the price target from $47.00 to $50.00.
JP Morgan analyst Andrew C. Steinerman commented, "Thursday evening, Cintas reported 3QF13 (Feb) revenues of $1,076mln, ~2% above our estimate, as organic same-day basis (SDB) revenue growth rose to 6.9% y/y (from 3.4% y/y in 2QF13 (Nov)). 3QF13 EPS was $0.60, slightly below our estimate of $0.63. … The new healthcare regulations represent a prospective CY2014 margin headwind, but in a healthy economy CTAS should have high enough top-line growth and operating levers to overcome this headwind, in our view."
Cintas closed at $45.93 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in